Search Results - "Scholten, Felicitas"

Impact of RAS status and prior targeted therapy on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in daily practice. Final results of the QoLiTrap prospective non-interventional study by Hofheinz, Ralf Dieter, Kröning, Hendrik, Zahn, Mark-Oliver, Scholten, Felicitas, Derigs, Hans-Günter, Pederiva, Stefanie, Anchisi, Sandro, Bohanes, Pierre Oliver, Gruenberger, Birgit, Windemuth-Kieselbach, Christine, Piringer, Gudrun, Thaler, Josef, Moos, Roger von

“…Abstract only e15570 Background: The anti-angiogenic fusion protein aflibercept targets VEGF-A, VEGF-B and PIGF. It is approved in combination with FOLFIRI for…”
Get full text

Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study by Piringer, Gudrun, Thaler, Josef, Anchisi, Sandro, Geffriaud-Ricouard, Christine, Gueldner, Max, Scholten, Felicitas, Derigs, Hans-Günter, Bohanes, Pierre, Grünberger, Birgit, Schwarz, Leonora, von Moos, Roger, Hofheinz, Ralf-Dieter

“…Colorectal cancer (CRC) mainly affects older patients. The pivotal VELOUR phase III trial of aflibercept plus FOLFIRI in metastatic CRC (mCRC) included only…”
Get full text

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study by Hofheinz, Ralf-Dieter, Anchisi, Sandro, Grünberger, Birgit, Derigs, Hans G, Zahn, Mark-Oliver, Geffriaud-Ricouard, Christine, Gueldner, Max, Windemuth-Kieselbach, Christine, Pederiva, Stefanie, Bohanes, Pierre, Scholten, Felicitas, Piringer, Gudrun, Thaler, Josef, von Moos, Roger

“…Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy…”
Get full text